Posted by Adam Awdish on
Pooled Human AB Serum Plasma Derived from Innovative Research was used in the following study:
Michael Maschan, Paolo F. Caimi, Jane Reese-Koc, Gabriela Pacheco Sanchez, Ashish A. Sharma, Olga Molostova, Larisa Shelikhova, Dmitriy Pershin, Alexey Stepanov, Yakov Muzalevskii, Vinicius G. Suzart, Folashade Otegbeye, David Wald, Ying Xiong, Darong Wu, Adam Knight, Ibe Oparaocha, Beatrix Ferencz, Andre Roy, Andrew Worden, Winfried Kruger, Michael Kadan, Dina Schneider, Rimas Orentas, Rafick-Pierre Sekaly, Marcos de Lima & Boro Dropulić
December 10, 2021
Pediatric B-acute lymphoblastic leukemia (B-ALL) is typically a highly curable disease, however, about 3% of patients will suffer from refractory disease and up to 15% of patients can relapse after treatment with chemotherapy. Normal treatment for Non-Hodgkin’s lymphoma (NHL) involves combination chemotherapy treatment, and treatments are generally successful.
One specific 95 kDa glycoprotein found on the surfaces of B-cells expressed by most B-cell malignancies, including NHL and B-ALL, is CD19. Immunotherapies that target CD19, namely those utilizing Chimeric antigen receptor (CAR) T cells, have been shown to be effective in treating patients with B-cell malignancies. The ability to manufacture CAR T cells at the place-of-care would be beneficial as it would diminish the cost and time associated with the need to cryopreserve and transport cells from satellite facilities, improving the performance and accessibility of treatment for B-cell malignancies.
Researchers in this study developed place-of-care anti-CD19 CAR (CAR19) T cells made of 4-1BB co-stimulatory and TNFRSF19 transmembrane domains which demonstrated anti-tumor properties. Testing showed this treatment induced Complete Remission rates of 89% of B-ALL and 73% for NHL.
Related products available from Innovative Research also include: